Phanthipha Wongwai a, Pritaporn Kingkaew b, Somkiat Asawaphureekorn a, Tharatip Kolatat c aDepartment of Ophthalmology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40000, Thailand bHealth Intervention and Technology Assessment Program (HITAP), Nonthaburi 11000, Thailand cDepartment of Pa

Boonying Siribumrungwong1, Pinit Noorit2, Chumpon Wilasrusmee3, Pattara Leelahavarong4, Ammarin Thakkinstian5 and Yot Teerawattananon4 Abstract Objectives: To conduct economic evaluations of radiofrequency ablation, ultrasound-guided foam sclerotherapy and surgery for great saphenous vein ab

Thanthima Suwanthawornkul1, Thunyarat Anothaisintawee2*, Abhasnee Sobhonslidsuk3, Ammarin Thakkinstian4, Yot Teerawattananon1 1 Health Intervention and Technology Assessment Program, Ministry of Public Health, Nonthaburi, Thailand, 2 Department of Family Medicine, Faculty of Medicine, Ramathibodi

Mark Blecher, National Treasury, South Africa Anban Pillay, National Department of Health, South Africa Walaiporn Patcharanarumol, International Health Policy Program, Ministry of Public Health, Thailand Warisa Panichkriangkrai, International Health Policy Program, Ministry of Public Health

Improving quality of primary care through financial incentives: the case of Thailand. Paramjit Gill1, Rachel Foskett-Tharby1, Francoise Cluzeau2, Sripen Tantivess3 and Yot Teerawattananon3 1National Collaborating Centre for Indicator Development, University of Birmingham, UK 2NICE International

Siriporn Pooripussarakul1, Arthorn Riewpaiboon1* , David Bishai2, Charung Muangchana3 and Sripen Tantivess4 Abstract Background: There is a need to identify rational criteria and set priorities for vaccines. In Thailand, many licensed vaccines are being considering for introduction into the Ex

Abstract BACKGROUND: Pegylated interferon alpha 2a, alpha 2b and ribavirin have been included to the National List of Essential Medicines (NLEM) for treatment of only chronic hepatitis C genotypes 2 and 3 in Thailand. This reimbursement policy has not covered for other genotypes of hepatitis

Sripen Tantivess & Viroj Tangcharoensathien Abstract Thailand achieves universal health coverage through the introduction of 3 benefit schemes: the Civil Servant Medical Benefit Scheme (CSMBS), Social Security Scheme, and Universal Coverage Scheme. The primary benefit package of these sche

Abstract Introduction. Many countries have introduced pay-for-performance (P4P) models to encourage health providers and institutions to provide good quality of care. In 2013, the National Health Security Office of Thailand introduced P4P, based on the UK Quality and Outcomes Framework (QOF),

Objective: This study aims to compare the lifetime costs and health outcomes of both first-line and sequential combination treatments with standard treatment for pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD) (PAH-CHD) patients. Methods: A cost-utility analysis